BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
February 23, 2022 7:00 AM ESTQ4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021
ORLADEYO net revenue in 2022 expected to be no less than $250 million
Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... More



